Acaluxen 100 mg contains acalabrutinib, an oral medicine in the Bruton tyrosine kinase (BTK) inhibitor class. Everest Pharmaceuticals Ltd. identifies Acaluxen as acalabrutinib 100 mg. Its official product information also describes a 60-capsule container. Acalabrutinib is a targeted medicine used in selected adult B-cell malignancies. Current U.S. labeling includes chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and specified mantle cell lymphoma (MCL) treatment settings. However, approved uses can differ between countries and products.

Because Acaluxen is a prescription anticancer medicine, treatment should be directed by an appropriately qualified healthcare professional. The correct dose can depend on the disease, treatment combination, drug interactions, liver function, and adverse reactions. Before ordering, confirm the product name, strength, manufacturer, packaging, batch information, and applicable prescription requirements. Product-specific documentation should take priority over general information about acalabrutinib.

Acaluxen 100 mg Product

Product detail	Information
Product name	Acaluxen 100 mg
Active ingredient	Acalabrutinib
Strength	100 mg
Dosage form	Capsule, according to Everest product information
Drug class	Bruton tyrosine kinase inhibitor
Therapeutic area	Hematology/oncology
Manufacturer	Everest Pharmaceuticals Ltd.
Stated pack	60 capsules
Product type	Prescription medicine

Everest Pharmaceuticals lists Acaluxen among its products and identifies it as acalabrutinib 100 mg. Its product information states that each Acaluxen capsule contains 100 mg acalabrutinib.

What Is Acaluxen 100 mg Used For?

Acaluxen contains acalabrutinib, which inhibits BTK signaling in B cells. The specific approved uses of an Acaluxen product depend on its applicable regulatory authorization.

Current U.S. acalabrutinib labeling covers adults with:

• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)
• Mantle cell lymphoma (MCL) after at least one prior therapy
• Previously untreated MCL in adults who are not eligible for autologous hematopoietic stem-cell transplantation, when used with bendamustine and rituximab.

Do not assume that every approved indication in one country applies to Acaluxen in another country. The prescription and local product information should determine the appropriate use.

How Acalabrutinib Works

Acalabrutinib is a selective small-molecule BTK inhibitor. BTK is an important signaling protein within the B-cell receptor pathway. This pathway contributes to B-cell activation, survival, movement, and other cellular functions. Acalabrutinib and its active metabolite, ACP-5862, bind covalently to a cysteine residue in the BTK active site. This inhibits BTK enzymatic activity and disrupts signaling that can support malignant B-cell survival and proliferation. In simple terms, acalabrutinib interferes with an important signal used by certain abnormal B cells. This targeted mechanism does not mean the medicine is free from serious adverse effects. Appropriate monitoring remains important throughout treatment.

Key Benefits of Acaluxen

Acaluxen provides acalabrutinib in a 100 mg oral dosage form.

Potential treatment benefits include:

• Targeted inhibition of BTK signaling.
• Oral administration.
• Use in selected adult B-cell malignancies.
• A dosing schedule established for approved acalabrutinib treatment settings.
• Availability as an Everest Pharmaceuticals product.

The medicine should only be used for an appropriate indication determined by the treating clinician.

Active Ingredient

The active ingredient is acalabrutinib 100 mg. Acalabrutinib belongs to the BTK inhibitor class of targeted anticancer medicines. It is not a conventional chemotherapy medicine.  The official Everest product information identifies each Acaluxen capsule as containing acalabrutinib 100 mg.

Dosage and Administration

The appropriate Acaluxen dose must be determined by the prescribing healthcare professional. For current U.S. acalabrutinib capsule labeling, the recommended dose for approved MCL, CLL and SLL settings is generally 100 mg orally approximately every 12 hours. Treatment continues according to the relevant disease setting until disease progression or unacceptable toxicity.

The dose may require modification because of:

• Drug interactions
• Adverse reactions
• Treatment combinations
• Liver impairment
• Other clinical considerations

Do not change your dose without medical advice.

How to Take Acaluxen

If your prescription is for the capsule formulation:

1. Take Acaluxen exactly as prescribed.
2. Swallow the capsule whole with water.
3. Do not open, break or chew the capsule.
4. It may be taken with or without food under current U.S. capsule labeling.
5. Take doses at the prescribed interval.
6. Do not take extra capsules to compensate for a missed dose.

Missed Dose

Under current U.S. capsule labeling, if a dose is missed by more than three hours, skip that dose. Take the next dose at the regular scheduled time. Do not take an extra dose to replace the missed capsule. If you are unsure how to manage a missed dose, contact your healthcare professional.

Available Strengths

The Acaluxen product covered on this page is: Acaluxen 100 mg — acalabrutinib 100 mg. Everest Pharmaceuticals’ product information identifies Acaluxen as a 100 mg capsule. Do not substitute another strength or formulation without medical instructions.

Available Pack Size

Everest Pharmaceuticals’ prescribing information states that Acaluxen is supplied in an HDPE container containing 60 capsules, with each capsule containing 100 mg acalabrutinib. Always confirm the actual pack supplied before use.

Who Can Use Acaluxen?

Acaluxen may be prescribed to appropriate adult patients when acalabrutinib is indicated for their disease.

Eligibility depends on factors such as:

• Diagnosis
• Previous cancer treatment
• Treatment plan
• Current medicines
• Liver function
• Blood counts
• Infection history
• Bleeding risk
• Heart rhythm history

The medicine should not be started simply because symptoms resemble a blood cancer. A confirmed diagnosis and appropriate medical assessment are essential.

Who Should Not Use It Without Medical Review?

Do not self-start Acaluxen.

Tell your healthcare professional if you:

• Have significant bleeding problems.
• Take anticoagulants or antiplatelet medicines.
• Have an active or recurrent infection.
• Have low blood-cell counts.
• Have liver disease.
• Have a history of atrial fibrillation or another cardiac arrhythmia.
• Are pregnant or planning pregnancy.
• Are breastfeeding.
• Take medicines that affect CYP3A.
• Take medicines that reduce stomach acid.

Current U.S. labeling advises avoiding acalabrutinib in patients with severe hepatic impairment.

Warnings and Precautions

Acalabrutinib can cause serious adverse reactions. Patients should understand these risks before treatment.

Bleeding

Serious hemorrhage, including life-threatening or fatal bleeding, has been reported. The risk may be higher when acalabrutinib is used with anticoagulants or antiplatelet medicines. Tell your healthcare team about all medicines that affect blood clotting.

Infections

Serious infections can occur during treatment. Contact your healthcare team promptly if you develop concerning symptoms of infection. Current labeling recommends monitoring for signs of infection.

Low Blood Counts

Acalabrutinib can cause cytopenias, including neutropenia, anemia, and thrombocytopenia. Healthcare professionals may monitor complete blood counts during treatment.

Second Primary Malignancies

Second primary cancers have been reported, including skin cancers. Patients should follow medical advice about sun protection and routine health monitoring.

Heart Rhythm Problems

Atrial fibrillation and atrial flutter have occurred during acalabrutinib treatment. Tell your healthcare professional if you develop palpitations, an irregular heartbeat, dizziness, or shortness of breath.

Liver Problems

Hepatotoxicity, including drug-induced liver injury, is an important warning in current labeling. Healthcare professionals may monitor liver function when appropriate.

Possible Side Effects

Acalabrutinib can cause side effects, although not everyone experiences them.

Reported adverse reactions include:

• Headache
• Diarrhea
• Muscle or joint pain
• Upper respiratory tract infection
• Neutropenia
• Anemia
• Thrombocytopenia

More serious risks include bleeding, serious infections, cytopenias, second primary malignancies, cardiac arrhythmias, and liver injury. Seek urgent medical attention for severe bleeding, serious infection symptoms, significant breathing problems, severe weakness, or symptoms suggesting an abnormal heart rhythm.

Drug Interactions

Acalabrutinib interacts with several medicines.

CYP3A inhibitors

Strong CYP3A inhibitors can increase acalabrutinib exposure and may increase toxicity. Current U.S. labeling recommends avoiding strong CYP3A inhibitors when possible. Moderate CYP3A inhibitors can also increase exposure and may require dose modification.

CYP3A inducers

Strong CYP3A inducers can reduce acalabrutinib exposure and may reduce its activity. Tell your healthcare professional about all prescription and non-prescription medicines before starting treatment.

Acid-reducing medicines

Gastric-acid reducing medicines can affect acalabrutinib exposure depending on the formulation and labeling.

Current U.S. capsule labeling advises:

• Avoiding proton pump inhibitors.
• Taking H2-receptor antagonists at a specified interval from acalabrutinib.
• Separating antacid administration from acalabrutinib by at least two hours.

Do not stop an acid-reducing medicine without discussing it with your healthcare professional.

Pregnancy and Breastfeeding

Acalabrutinib may cause fetal harm based on animal studies. Women who are pregnant, planning pregnancy, or able to become pregnant should discuss treatment and contraception with their healthcare professional. The current U.S. labeling advises avoiding breastfeeding during treatment and for at least two weeks after the final dose.

Kidney and Liver Considerations

Acalabrutinib undergoes relatively little renal elimination. Available pharmacokinetic information has not shown a clinically relevant difference in mild or moderate renal impairment, while severe renal impairment and dialysis have not been adequately studied. Liver function is more clinically important because acalabrutinib is metabolized in the liver. Severe hepatic impairment requires particular caution, and current U.S. labeling advises avoiding CALQUENCE in severe hepatic impairment. Your prescriber should determine whether dose modification or an alternative treatment is appropriate.

Monitoring During Treatment

Depending on your treatment plan, your healthcare team may monitor:

• Complete blood counts.
• Signs of infection.
• Bleeding symptoms.
• Heart rhythm symptoms.
• Liver function.
• Treatment response.
• Other adverse effects.

Monitoring frequency depends on your disease, treatment combination, and overall health.

Storage Instructions

Everest Pharmaceuticals’ product information states that Acaluxen should be stored below 30°C, protected from light and kept out of reach of children. Keep the medicine in its original packaging unless your pharmacist provides different instructions. Do not use medicine from damaged or questionable packaging.

Manufacturer Information

Everest Pharmaceuticals Ltd. lists Acaluxen among its products and identifies the active ingredient as acalabrutinib 100 mg. The company’s product information also identifies its manufacturing location in Kanchpur, Narayanganj, Bangladesh.

Prescription Requirements

Acaluxen is a prescription anticancer medicine. A legitimate purchase should follow the prescription and regulatory requirements applicable to the customer’s country. Do not purchase acalabrutinib for self-treatment. The correct indication, dosage and treatment duration must be determined by a qualified healthcare professional.

Why Buy Acaluxen Through a Responsible Pharmacy or Supplier?

When purchasing a prescription oncology medicine, price should not be the only consideration.

A responsible supplier should provide:

• Clear product identification.
• Manufacturer information.
• Appropriate prescription handling.
• Transparent availability.
• Secure ordering procedures.
• Product packaging information.
• Customer support.
• Clear shipping terms.
• A process for addressing damaged or questionable products.

For international orders, customers should also confirm that the medicine can legally be supplied and received in their destination country. For Selxen: publish only those shipping, pharmacy, licensing, payment, prescription-verification, and delivery claims that can be independently documented on the live website.

Shipping and Delivery

Acaluxen may require specialized handling because it is a prescription oncology medicine.

Before placing an order, customers should confirm:

1. Destination availability.
2. Prescription requirements.
3. Product availability.
4. Expected dispatch time.
5. Shipping method.
6. Any customs or import requirements.
7. Procedures for damaged packages.

Do not publish a guaranteed delivery time unless the logistics provider and destination support that guarantee.

Global Access Through Selxen

Selxen is identified for this product as the global access and knowledge bridge. The product page should explain the ordering process clearly without implying that every country has identical regulatory requirements.

Before You Order Acaluxen 100 mg

Use this quick checklist:

• Confirm your prescription.
• Confirm the active ingredient is acalabrutinib.
• Confirm the strength is 100 mg.
• Confirm the manufacturer.
• Check the pack and expiry date.
• Ask about availability.
• Review prescription requirements.
• Disclose your current medicines.
• Ask about shipping conditions.
• Verify the product when an official verification system is available.

Conclusion

Acaluxen 100 mg contains acalabrutinib, a BTK inhibitor used in selected adult B-cell malignancies. Its established treatment settings include CLL, SLL, and specified MCL populations, although exact regulatory indications depend on the applicable jurisdiction and product information. Because Acaluxen is a prescription anticancer medicine, it should be used under professional medical supervision. Important safety considerations include bleeding, infections, low blood counts, cardiac arrhythmias, second primary malignancies, and liver injury. For a legitimate purchase, confirm the prescription, manufacturer, packaging, batch information, and applicable product documentation. Everest Pharmaceuticals identifies Acaluxen as acalabrutinib 100 mg and provides product information for the medicine.

FAQs About Acaluxen 100 mg

What happens if I miss an Acaluxen dose?

Under current U.S. capsule labeling, if the missed dose is more than three hours late, skip it and take the next dose at its normal time. Do not take extra capsules.

What are the important side effects of acalabrutinib?

Important risks include bleeding, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and liver injury. Headache, diarrhea, muscle or joint pain, and upper respiratory infections can also occur.

Can acalabrutinib interact with other medicines?

Yes. CYP3A inhibitors and inducers can affect acalabrutinib exposure. Acid-reducing medicines can also require special management. Always provide your healthcare professional with a complete list of medicines and supplements.

Can I take Acaluxen during pregnancy?

Acalabrutinib may cause fetal harm based on animal data. Anyone who is pregnant or planning pregnancy should discuss treatment with their healthcare professional before taking the medicine.

How should Acaluxen be stored?

Everest Pharmaceuticals’ product information states that Acaluxen should be stored below 30°C, protected from light, and kept away from children.

Who manufactures Acaluxen 100 mg?

Acaluxen 100 mg is manufactured by Everest Pharmaceuticals Ltd. Everest’s official product listings identify Acaluxen as acalabrutinib 100 mg.